CoreRx Named to Tampa’s 2011 Fast 50
CoreRx, fast becoming a world-recognized leader in early drug contract development, was announced today as one of Tampa Bay’s Fast 50 companies. The Tampa Bay Business Journal’s Fast 50 is a list of the fastest growing privately held companies in Tampa Bay over a span of three years. Last year, CoreRx was recognized as the 6th fastest growing company in the Tampa Bay region.
Combination Products should be considered
According to Pharmaceutical Technology, there has been a surge in the number of combination product (i.e. where a drug product is combined with a medical device) launches in recent years and this trend is set to continue as more companies seek to extend the life of existing branded medicines.
CoreRx™ Inc. announces sponsorship of Pharmaceutical Strategy Series’ executive forum
Combination products provide new avenues for the development of improved drug-drug, drug-device products, as well as generating opportunities for companies to leverage their existing products & patent life. This forum will focus on the development challenges, commercial and partnering strategies, as well as the market implications of combination products.

